The Concomitant Use Of Proton Pump Inhibitors And Pazopanib In Patients With Soft-Tissue Sarcoma: Is It Really To Be Avoided?

The Concomitant Use Of Proton Pump Inhibitors And Pazopanib In Patients With Soft-Tissue Sarcoma: Is It Really To Be Avoided?

Objectives: Pazopanib is an orally administered drug and has approval for the treatment of advanced Soft Tissue Sarcomas (aSTS). The absorption of pazopanib is pH-dependent. Acid-Reducing drugs such as proton pump inhibitors (PPI) may reduce the bioavailability of pazopanib. The primary purpose of...

Full description

Bibliographic Details
Main Authors: Mustafa, Yasin, Murat, Melek Karakurt, Muhammet Ali, Mehmet
Format: Article
Language:English
Published: Dicle University Medical School 2020-03-01
Series:Dicle Medical Journal
Subjects:
pazopanib
proton pump inhibitor
concomitant
survival
sarcoma
Online Access:http://diclemedj.org/upload/sayi/76/Dicle%20Med%20J-04039.pdf

Similar Items

Similar Items